Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Ingmar Bruns Acquires 20,000 Shares

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) insider Ingmar Bruns bought 20,000 shares of the firm’s stock in a transaction on Thursday, February 6th. The stock was purchased at an average cost of $2.28 per share, with a total value of $45,600.00. Following the completion of the transaction, the insider now directly owns 36,629 shares of the company’s stock, valued at approximately $83,514.12. The trade was a 120.27 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Zentalis Pharmaceuticals Trading Up 3.8 %

Shares of NASDAQ ZNTL traded up $0.08 during mid-day trading on Wednesday, hitting $2.16. The company had a trading volume of 938,298 shares, compared to its average volume of 2,729,571. The stock’s 50-day moving average price is $2.72 and its 200-day moving average price is $3.15. Zentalis Pharmaceuticals, Inc. has a 1 year low of $1.61 and a 1 year high of $18.07. The company has a market capitalization of $153.93 million, a price-to-earnings ratio of -0.87 and a beta of 1.81.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.36. As a group, equities research analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ZNTL. Erste Asset Management GmbH bought a new stake in Zentalis Pharmaceuticals during the third quarter worth about $37,000. Paloma Partners Management Co bought a new stake in Zentalis Pharmaceuticals during the third quarter worth about $37,000. Prudential Financial Inc. bought a new stake in Zentalis Pharmaceuticals during the fourth quarter worth about $39,000. Aigen Investment Management LP bought a new stake in Zentalis Pharmaceuticals during the third quarter worth about $41,000. Finally, Ieq Capital LLC bought a new stake in Zentalis Pharmaceuticals during the fourth quarter worth about $46,000.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ZNTL. Wedbush reissued a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. UBS Group decreased their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Wells Fargo & Company decreased their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. HC Wainwright decreased their target price on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. Finally, Guggenheim decreased their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.